Moderna's stock climbed 4% after strong Phase 3 melanoma vaccine trial results, despite a downgrade from William Blair citing valuation concerns after a 636% yearly gain. The trial showed Moderna and Merck's vaccine reduced melanoma recurrence risk by 42% compared to Keytruda alone, suggesting a potential new standard of care. Investors are watching upcoming trial results in renal cancer and manufacturing scalability, which will influence Moderna's future growth beyond melanoma. The stock's rise reflects optimism about its cancer pipeline, even as some analysts caution the price may already factor in broad success.
Moderna's stock price at USD 215.51 is trading closer to its 52-week high of USD 245.81, showing a strong 3.63% gain on Pluang as of Oct 28, 2026 23:21 WIB, compared to Novavax's more modest 1.70% rise at USD 10.19, well below its 52-week high of USD 12.82. BioNTech's price of USD 87.78 is near its 52-week low of USD 83.89, with a smaller 0.83% increase. This contrast highlights Moderna's stronger momentum in the health sector on Pluang currently.
Moderna's stock fell about 7.4% following the release of Phase 3 trial data for its experimental cancer vaccine, intismeran, developed with Merck. The results tempered investor enthusiasm, reflecting that expectations had been very high. Merck's shar...
Moderna's stock fell 7% after its personalized melanoma vaccine, despite meeting its primary goal in a late-stage trial, showed less impact on distant cancer spread than earlier studies suggested. This has led investors to reassess the commercial pot...
Biotech stocks are rallying strongly in 2026, with the iShares Biotechnology ETF up 24% year-to-date, building on a 28% gain in 2025. Moderna leads with a 587% surge despite a recent dip after positive cancer vaccine data leaked. The sector's growth ...
